Publications
9 shownSupplementary Figure S7 from Efficacy of a Small-Molecule Inhibitor of Kras<sup>G12D</sup> in Immunocompetent Models of Pancreatic Cancer
<p>Effects of MRTX1133 in KPC/Y and subcutaneous models</p>
Supplementary Figure S1 from Efficacy of a Small-Molecule Inhibitor of Kras<sup>G12D</sup> in Immunocompetent Models of Pancreatic Cancer
<p>MRTX1133 selectively inhibits KRASG12D and downstream MAPK signaling in vitro</p>
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients’ advanced disease...
Supplementary Materials from Efficacy of a Small-Molecule Inhibitor of Kras<sup>G12D</sup> in Immunocompetent Models of Pancreatic Cancer
<p>Supplementary Figures and Table with legend arranged in a single presentable package</p>
Supplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of Kras<sup>G12D</sup> in Immunocompetent Models of Pancreatic Cancer
<p>MRTX1133 exerts in vivo effects early in treatment</p>
Supplementary Figure S4 from Efficacy of a Small-Molecule Inhibitor of Kras<sup>G12D</sup> in Immunocompetent Models of Pancreatic Cancer
<p>MRTX1133 elicits changes in the tumor stroma and vasculature</p>
Supplementary Figure S3 from Efficacy of a Small-Molecule Inhibitor of Kras<sup>G12D</sup> in Immunocompetent Models of Pancreatic Cancer
<p>MRTX1133 reduces metastatic burden in a tail vein model</p>
Supplementary Figure S6 from Efficacy of a Small-Molecule Inhibitor of Kras<sup>G12D</sup> in Immunocompetent Models of Pancreatic Cancer
<p>KRASG12D inhibition alters the tumor immune microenvironment</p>
Frequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 9
- Citations
- 1,146
- Institution
- UCLA Jonsson Comprehensive Cancer Center
External Links
Identifiers
- ORCID
- 0000-0002-1175-2545
Impact Metrics
h-index: Number of publications with at least h citations each.